Background: Colitis-associated cancer (CAC) is caused by chronic intestinal inflammation and often results from refractory inflammatory bowel
C hronic intestinal inflammation, as that observed in patients with inflammatory bowel disease (IBD), is a risk factor of colitis-associated cancer (CAC). 1,2 IBD comprises Crohn's disease (CD) and ulcerative colitis (UC) and is characterized by marked infiltration of inflammatory cells into the affected mucosa. However, mechanisms underlying the pathogenesis of CAC are poorly understood. Previously, we found that induction of stress response proteins Cirp and heat shock protein A4 (HSPA4) in patients with long-standing inflammation of the mucosa promoted the development of refractory colitis and CAC. 3, 4 A recent study showed that Cirp is released into the circulation. 5 Analysis of serum Cirp levels may increase the identification rate of patients who are at a high risk of developing CAC and hepatocellular carcinoma. 3, 6 Moreover, HSPA4 expression could predict poor therapeutic response of patients with IBD to steroids. 4 These data suggest that long-term inflammation induces treatment resistance, refractory clinical course, and eventually cancer through the stress response of host.
Crypt stem cells represent the cells of origin of intestinal neoplasias. Both mouse and human intestinal stem cells can be cultured in a medium containing stem cell-specific factors, such as R-spondin and Noggin, over long periods to produce epithelial organoids that remain genetically and phenotypically stable. 7 Colorectal cancers arise from the loss of homeostasis of the intestinal epithelium and hyperproliferation of the crypt epithelium. Kim et al 8 showed that R-spondin induced hyperproliferation of the crypt epithelium in mice. Consistently, R-spondin has been reported to promote the development of colorectal cancer. 9 Endogenous R-spondin is mainly localized in intestinal epithelial cells. 10 Similar to Cirp and HSPA4, RNA-binding motif protein 3 (RBM3) is induced under various conditions, including hypoxia Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (http://www.ibdjournal.org).
and cold stress 11, 12 and is upregulated in several cancers. [13] [14] [15] In the present study, we examined whether RBM3 was involved in the tumorigenesis of CAC by using human colonic tissue samples and Rbm3-deficient (Rbm3 2/2 ) mice and found that RBM3 promoted colorectal tumorigenesis by inhibiting apoptosis and by increasing R-spondin expression in the gut. In patients with IBD, refractory inflammation was associated with increased RBM3 expression in the colonic mucosa, which enhanced the risk of CAC. To the best of our knowledge, this is the first study on RBM3 as a possible regulator of tumorigenesis in patients with IBD.
MATERIALS AND METHODS

Human Tissue Samples
In all, 263 intestinal mucosa samples from patients with IBD (36 patients with CD and 209 patients with UC) and 18 normal colonic mucosa samples from patients without IBD were obtained endoscopically at Kindai University Hospital between January 2011 and March 2014. The study participants comprised 38 patients in remission and 207 patients with active IBD, including 100 patients with refractory IBD. The tissue samples were collected from involved areas of the intestine. Active inflammation was defined as a Mayo endoscopic score of $2 in patients with UC and presence of ulcers in patients with CD or presence of symptoms. Patients with refractory IBD were defined as those with active IBD for .6 months at the time of biopsy. Colonic mucosae surrounding colonic tumors that were endoscopically resected were used as control mucosae in Figure 4A . CAC specimens were obtained from 10 patients who had undergone surgery. Informed consent for utilization of the tissue samples for analysis was obtained from all the patients. All study protocols conformed to the ethical guidelines of the Declaration of Helsinki (1975) and were approved by the appropriate institutional review boards.
Mice and Treatment
Rbm3 2/2 mice were obtained from Prof. Tadatsugu Taniguchi of the University of Tokyo. Sex-and age-matched C57BL/6:129P Rbm3 2/2 mice and their wild-type (WT) littermates (age, 8-12 weeks) received 2.5% (wt/vol) dextran sodium sulfate (DSS; molecular weight, 36-50 kDa; MP Biomedicals, Solon, OH) in drinking water for 7 days. For developing the murine model of CAC, the mice were intraperitoneally injected with 12.5 mg/kg azoxymethane (AOM; Sigma-Aldrich, Tokyo, Japan). After 5 days, the mice were given drinking water containing 2.0% DSS for 5 days, followed by regular water for 16 days. This cycle was repeated 3 times. Next, the mice were given drinking water containing 1.5% DSS for 4 days, followed by regular water for 7 days. After euthanization, the colon was excised from the ileocecal junction to the anus, cut longitudinally, and prepared for histological evaluation. Inflammatory cell infiltration score and epithelial injury score were assessed as described previously. 3 Bone marrow transplantation experiments were performed as described previously, 3 with slight modifications. Bone marrow (BM) from the tibia and femur was washed twice in Hanks balanced salt solution, and 10 7 BM cells were injected into the tail vein of lethally irradiated (11 Gy) recipient mice. All animal procedures were performed in accordance with approved protocols and with the recommendations for the proper care and use of laboratory animals. This study was approved by the Medical Ethics Committee of the Faculty of Medicine, Kindai University.
Biochemical and Immunohistochemical Analyses
Quantitative polymerase chain reaction, immunoblotting, and immunohistochemical analysis were performed as described previously. 3, 4, 16 Primer sequences for quantitative polymerase chain reaction are given in Table 1 (Supplemental Digital Content 1, http://links.lww.com/IBD/B381). The following antibodies were used for performing immunoblotting: anti-b-actin antibody (Sigma-Aldrich) and anti-Bcl-xL antibody (Cell Signaling, Danvers, MA). Anti-RBM3 polyclonal antibody was developed as described previously. 11 Immunohistochemical analysis was performed using ImmPRESS reagents (Vector Laboratory, Burlingame, CA), according to the manufacturer's recommendations. Apoptosis in paraffin-embedded tissue sections was determined by performing immunofluorescent TdTmediated dUTP nick-end labeling (TUNEL) assay with In Situ Apoptosis Detection Kit (Takara, Tokyo, Japan) and a confocal laser microscope (FluoView FV10i; Olympus, Tokyo, Japan), according to the manufacturer's instructions. Nuclei were stained with 4,6 0 -diamidino-2-phenylindole to count the total number of cells per crypt. A minimum of 10 crypts with a normal morphology were counted per section. TUNEL-positive crypts were counted from 100 randomly selected crypts.
Statistical Analysis
Differences were analyzed using Student's t test, and relationship between the expression of several genes was analyzed using Spearman's rank correlation test. Variables of more than 2 conditions were compared using analysis of variance and post hoc Tukey-Kramer honestly significant difference multiple comparison test. P , 0.05 was considered statistically significant.
RESULTS
RBM3 Expression Is Significantly Correlated with Bcl-xL and Stem Cell Marker Expression in the Colonic Mucosa of Patients with IBD
Long-standing intestinal inflammation increases the expression of cold-inducible proteins, such as Cirp and HSPA4, in the colonic mucosa of patients with IBD. 3, 4 Because RBM3 is also induced by cold shock, we examined the association between the expression of RBM3 and that of other stress response proteins. RBM3 expression was significantly correlated with HSPA4, Cirp, and HSP27 expression (linear coefficients of 0.67, 0.58, and 0.52, respectively) in the colonic mucosa of patients with UC ( Fig. 1A-C) . Like Cirp and HSPA4, RBM3 expression was also correlated with Bcl-2 and Bcl-xL expression ( Fig. 1D, E) .
Cirp and HSPA4 increase the number of Sox2-positive cells in the chronically inflamed colon. 3, 4 Moreover, expression of Cirp and HSPA4 is correlated with that of several stem cell markers such as Sox2 and Lgr5 in patients with IBD. 3, 4 RBM3 increases stem cell characteristics of colorectal cancer cells. 15 Expectedly, we observed that RBM3 expression was significantly correlated with Sox2 and Lgr5 expression in the colonic mucosa of patients with UC and CD (Fig. 2) . These data suggested that RBM3 functioned as a tumor promoter similar to stress response proteins Cirp and HSPA4.
In this study, patients with refractory IBD are defined as those with long-term colonic inflammation lasting for more than 6 months. In the colonic mucosa of refractory UC, a stronger correlation between RBM3 and Bcl-xL expression was found compared with that in nonrefractory active UC (Fig. 3A) . Similarly, we found a significant correlation between RBM3 and R-spondin expression in refractory UC but not in nonrefractory active UC (Fig. 3B) . These data suggest that RBM3 would regulate the expression of Bcl-xL and R-spondin in the setting of chronic inflammation.
RBM3 Expression Is Increased in Patients with Refractory IBD and CAC
In patients with refractory IBD, Cirp expression is higher in inflammatory cells than in epithelial cells, whereas HSPA4 expression is similar in both inflammatory and epithelial cells. 3, 4 Immunohistochemical analysis was performed to identify RBM3-expressing cells in the human intestine. In the chronically inflamed mucosa, RBM3 was expressed in both epithelial and inflammatory cells (Fig. 4A) , which was similar to that observed with HSPA4.
Cirp and HSPA4 expression increases in the colonic mucosa of patients with refractory IBD. 3, 4 We determined whether RBM3 expression was associated with the clinical status of patients with IBD. RBM3 expression levels increased in patients with refractory IBD who had long-term inflammation compared with those in controls, patients with IBD in remission, and patients with nonrefractory active IBD (Fig. 4B) . Chronic inflammation often precedes or accompanies many cancers. In this study, we observed that RBM3 was overexpressed in all the examined patients with CAC. Moreover, we observed that tumor cells preferentially but not exclusively expressed RBM3 (Fig. 4C) .
RBM3 Deficiency Attenuated Tumorigenesis in the Murine CAC Model
Chronic inflammation increases the risk of intestinal cancer in patients with IBD. 1, 2 To investigate the precise pathogenic mechanisms underlying IBD-associated colorectal carcinogenesis, we used an AOM-treated plus DSS-treated mouse model and examined the role of RBM3 in CAC. Treatment with AOM plus DSS significantly decreased the number but not the size of tumors in Rbm3 2/2 mice compared with those in WT mice (Fig. 5A, B) . Histological examination of hematoxylin and eosin-stained tissue sections of rolled-up colons did not show any differences between tumors in WT and Rbm3 2/2 mice (data not shown). However, RBM3 was expressed in both epithelial and inflammatory cells in the surrounding nontumor tissues and was preferentially expressed in tumor cells (Fig. 5C) , which is consistent with the findings in humans (Fig. 4) .
A decrease in tumor multiplicity in Rbm3 2/2 mice suggested that RBM3 may be playing a role in initiated or early tumor progenitor cell survival, as opposed to influencing tumor promotion, in which case similar number of tumors, but smaller tumors, would be expected. Given the involvement of RBM3 in the initiation of colorectal cancer, RBM3 might act in nontransformed colonic tissues rather than in established tumors. Therefore, we focused on nontumor tissues but not on tumor tissues. A stem cell-specific factor R-spondin is required for maintaining intestinal stem cells 7 and for inducing hyperproliferation of the crypt epithelium, 8 which would promote colorectal carcinogenesis. 9 Expression of R-spondin and cancer stem cell marker CD133 was decreased in the colons of Rbm3 2/2 mice compared with that in the colons of WT mice (Fig. 5D) . Expression of Noggin, another stem cell-specific factor, and Sox2 was slightly decreased in the colons of Rbm3 2/2 mice (Fig. 5D ).
Tumor-derived R-spondin augments b-catenin signaling. 9 However, expression of Lgr5, a downstream target gene of WNT/bcatenin signaling pathway, was not affected by Rbm3 deletion in the tumors of Rbm3 2/2 mice (data not shown).
Because RBM3 expression was significantly correlated with Bcl-xL expression in humans (Figs. 2 and 3) , we speculated that RBM3 regulated Bcl-xL expression. Expectedly, RBM3 deficiency decreased Bcl-xL expression in the colons of AOMtreated plus DSS-treated WT mice (Fig. 5D) . In contrast, Bcl-xL expression did not decrease in the tumors of AOM-treated plus DSS-treated Rbm3 2/2 mice (Fig. 5D ). Tumor and nontumor cells use different mechanisms to regulate gene expression. In tumor cells, Bcl-xL expression might be upregulated in an RBM3-independent manner. To confirm the role of RBM3 in apoptosis, we compared apoptosis induction in AOM-treated plus DSStreated WT and Rbm3 2/2 mice. Gut apoptosis was .2-fold higher in AOM-treated plus DSS-treated Rbm3 2/2 mice than in AOM-treated plus DSS-treated WT mice (Fig. 6A) . Bcl-xL was expressed in both epithelial cells and inflammatory cells (Fig. 6B) , which was consistent with the cellular distribution of RBM3 (Fig. 5C ). In tumors, RBM3 did not affect apoptosis induction (Fig. 6A) . Collectively, these results suggested that RBM3 protects intestinal cells from clearance due to inflammation in the murine CAC model.
To assess the effect of RBM3 on acute inflammation, experimental colitis was induced by treating mice with 2.5% DSS for 7 days. Inflammatory cell infiltration into the colon and epithelial injury were not affected by RBM3 disruption (see Fig.  S1A , B, Supplemental Digital Content 2, http://links.lww.com/ IBD/B382). No significant difference in messenger RNA levels of Bcl-xL, R-spondin, and CD133 was found between control mice and RBM3-deficient mice (see Fig. S2 , Supplemental Digital Content 3, http://links.lww.com/IBD/B383). In Caco2 cells, an immortalized line of human colorectal cancer cell, knockdown of RBM3, did not reduce the expression of Bcl-xL, R-spondin, and CD133 (see Fig. S3 , Supplemental Digital Content 4, http:// links.lww.com/IBD/B384). These data suggest that RBM3 might contribute to the enhanced colonic expression of these genes in a non-cell-autonomous manner.
RBM3 Upregulates R-Spondin Expression and Promotes Tumorigenesis Through Epithelial Cells
To functionally characterize the contribution of different cell populations to colorectal tumorigenesis, we developed RBM3-chimeric mice by using a combination of gamma irradiation and bone marrow transplantation. Nontransplanted control mice survived for ,2 weeks after the irradiation, indicating the ablation of endogenous BM. Transplanted mice were allowed to recover for 2 months before treating them with AOM plus DSS. Rbm3 2/2 mice transplanted with WT or Rbm3 2/2 BM had significantly smaller tumor burden than WT mice transplanted with WT BM (Fig. 6C) . WT mice transplanted with WT and Rbm3 2/2 FIGURE 5. Deficiency of RBM3 affects colonic tumorigenesis in the murine model of CAC. A, Typical examples of macroscopic tumorigenesis in the murine CAC model. Colons were cut longitudinally. B, Tumor number (WT mice, n ¼ 6; Rbm3 2/2 mice, n ¼ 6). C, Results of immunohistochemical staining of the colonic sections of AOM-treated plus DSS-treated WT and Rbm3 2/2 mice. Nontumor and tumor tissues obtained from the murine CAC model were stained with anti-RBM3 antibody; scale bar, 50 mm. D, RNA was extracted from nontumorous and tumorous colonic tissues. Relative levels of messenger RNA, as determined by performing quantitative polymerase chain reaction were normalized to those of actin messenger RNA. Level of each messenger RNA in untreated colonic tissues was given an arbitrary value of 1.0.
BM showed equivalent tumor numbers (Fig. 6C) . Rbm3 2/2 mice transplanted with Rbm3 2/2 or WT BM showed decreased R-spondin expression compared with WT mice transplanted with WT BM (Fig. 6D) . WT mice transplanted with WT and Rbm3 2/2 BM showed equivalent R-spondin expression levels (Fig. 6D) . These data indicated that RBM3 acted in the epithelial compartment to upregulate R-spondin expression and to enhance colorectal tumorigenesis. 
DISCUSSION
Stress response pathways play important roles in cancers arising from the loss of intestinal epithelial homeostasis. Stress triggers important adaptive responses to maintain homeostasis. One adaptive response is the induction of stress response proteins that act as chaperones and protect host from different stresses. However, increased and decreased stress response induces pathogenic conditions, such as inflammation and carcinogenesis. 17 Increased expression of stress response proteins Cirp and HSPA4 promotes the development of refractory colitis and colorectal cancers. 3, 4 Here, we showed that the stress response protein RBM3, which is upregulated in patients with refractory IBD, promoted colorectal tumorigenesis. The association between IBD and CAC is well established. The cumulative risk of developing colorectal cancer after 20 years is 7% in patients with UC and 8% in patients with CD. 2 In addition, it is clear that chronic inflammation plays a causative role in the transition to adenocarcinoma in IBD. 1, 2 Periodic colonoscopic surveillance with multiple biopsies is the conventional method for the early detection of colitis-associated dysplasia or cancer. However, such surveillance programs have several limitations, 18 and surveillance strategies need to be appropriately personalized. One of the challenges in colonoscopy for cancer surveillance is the lack of risk stratification. Therefore, analyzing the expression levels of stress response proteins may be effective for improving the identification of patients with IBD who are at a high risk of CAC. A future large-scale study involving patients with different stages of IBD will be crucial for determining whether Cirp, HSPA4, and RBM3 can be used as biomarkers for predicting the risk of colorectal carcinogenesis.
Although RBM3 messenger RNA and protein expression is upregulated in human tumors, the clinical implications of RBM3 in tumors are controversial. [13] [14] [15] [19] [20] [21] In contrast, RBM3 induces the growth of nontransformed cells in an anchorage-independent manner, 13 suggesting that RBM3 would expand transformed cells and act as a tumor promoter in nontransformed colonic mucosa. Because crypt stem cells represent the cells of origin of intestinal neoplasias, stem cell-specific factors, such as WNT, R-spondin, noggin, and epidermal growth factor, would promote the growth of cancer stem cells and intestinal stem cells in a paracrine manner. [7] [8] [9] Bone marrow transplantation experiments indicated that RBM3 upregulated R-spondin expression and promoted tumorigenesis through epithelial cell populations. We showed that RBM3 deficiency decreased Bcl-xL expression and increased apoptosis in nontumor tissues but not in tumor tissues of AOM-treated plus DSS-treated mice. RBM3 may protect early progenitor cells from clearance due to chronic inflammation. Because endogenous R-spondin is mainly localized in intestinal epithelial cells, 10 RBM3 might increase R-spondin expression through inhibiting apoptosis of epithelial cells. Furthermore, RBM3 can bind the transcripts to regulate the expression of several genes. 12 RBM3 might regulate expression of R-spondin and Bcl-xL genes posttranscriptionally as well.
Chronic inflammation enhances stress-induced Cirp and HSPA4 expression in patients with IBD. 3, 4 Here, we found that RBM3 expression increased because of refractory and long-term inflammation in the human colonic mucosa. Because Cirp and RBM3 are 2 evolutionarily conserved RNA-binding proteins that are transcriptionally upregulated in response to low temperature, 22 hypothermia might occur in the chronically inflamed colonic mucosa. Hypoxia, which increases in chronic inflammatory diseases, including IBD, upregulates Cirp and RBM3 expression, 12 which may be one of the reasons for the induction of RBM3 expression by chronic inflammation. However, the exact mechanisms underlying the regulation of RBM3 expression by longterm inflammation are unknown.
In summary, our results suggested that chronic inflammationinduced RBM3 inhibited apoptosis and augmented cancer stem cell expansion by upregulating Bcl-xL and R-spondin expression, thus increasing tumorigenesis. Thus, RBM3 would be a promising biomarker for predicting the risk of cancer and a new therapeutic target for cancer prevention in patients with IBD.
